Wall Street brokerages expect that Jounce Therapeutics Inc (NASDAQ:JNCE) will report earnings per share of ($0.80) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Jounce Therapeutics' earnings, with the lowest EPS estimate coming in at ($1.25) and the highest estimate coming in at ($0.65). Jounce Therapeutics posted earnings per share of $2.90 in the same quarter last year, which suggests a negative year over year growth rate of 127.6%. The firm is scheduled to report its next quarterly earnings report on Thursday, November 5th.
According to Zacks, analysts expect that Jounce Therapeutics will report full year earnings of ($3.05) per share for the current year, with EPS estimates ranging from ($3.63) to ($2.72). For the next year, analysts expect that the business will report earnings of ($2.44) per share, with EPS estimates ranging from ($2.75) to ($2.15). Zacks' earnings per share calculations are a mean average based on a survey of research analysts that follow Jounce Therapeutics.
Jounce Therapeutics (NASDAQ:JNCE) last issued its earnings results on Friday, August 7th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.72) by ($0.10).
A number of equities analysts recently issued reports on the stock. JPMorgan Chase & Co. reissued a "sell" rating on shares of Jounce Therapeutics in a research note on Friday, August 21st. BidaskClub raised shares of Jounce Therapeutics from a "strong sell" rating to a "sell" rating in a research note on Friday, September 11th. ValuEngine upgraded shares of Jounce Therapeutics from a "hold" rating to a "buy" rating in a report on Tuesday, September 1st. Zacks Investment Research cut shares of Jounce Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, August 13th. Finally, Roth Capital initiated coverage on shares of Jounce Therapeutics in a report on Friday, September 18th. They set a "buy" rating and a $28.00 price target on the stock. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company's stock. The stock has an average rating of "Hold" and an average price target of $13.75.
In related news, Director Barbara Gayle Duncan sold 10,000 shares of the firm's stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $10.00, for a total value of $100,000.00. Following the sale, the director now owns 10,000 shares in the company, valued at $100,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Kimberlee C. Drapkin sold 7,200 shares of the firm's stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $8.06, for a total transaction of $58,032.00. Following the completion of the sale, the chief financial officer now owns 61,708 shares in the company, valued at approximately $497,366.48. The disclosure for this sale can be found here. In the last quarter, insiders have sold 21,110 shares of company stock worth $176,378. Corporate insiders own 43.96% of the company's stock.
A number of hedge funds have recently modified their holdings of the stock. Principal Financial Group Inc. bought a new position in Jounce Therapeutics in the second quarter worth approximately $116,000. Nuveen Asset Management LLC raised its position in Jounce Therapeutics by 2.9% in the second quarter. Nuveen Asset Management LLC now owns 69,999 shares of the company's stock worth $483,000 after acquiring an additional 1,963 shares during the period. Charles Schwab Investment Management Inc. raised its position in Jounce Therapeutics by 22.0% in the second quarter. Charles Schwab Investment Management Inc. now owns 284,319 shares of the company's stock worth $1,962,000 after acquiring an additional 51,234 shares during the period. Jacobs Levy Equity Management Inc. raised its position in Jounce Therapeutics by 3.4% in the second quarter. Jacobs Levy Equity Management Inc. now owns 180,748 shares of the company's stock worth $1,247,000 after acquiring an additional 5,999 shares during the period. Finally, Sei Investments Co. raised its position in Jounce Therapeutics by 29.1% in the second quarter. Sei Investments Co. now owns 137,912 shares of the company's stock worth $949,000 after acquiring an additional 31,080 shares during the period. Institutional investors own 74.08% of the company's stock.
NASDAQ JNCE traded up $0.14 during trading on Friday, hitting $10.06. 294,019 shares of the company's stock traded hands, compared to its average volume of 625,505. The stock has a fifty day moving average of $8.27 and a two-hundred day moving average of $6.05. Jounce Therapeutics has a 12-month low of $2.85 and a 12-month high of $11.72. The firm has a market cap of $342.72 million, a P/E ratio of 16.23 and a beta of 1.69.
Jounce Therapeutics Company Profile
Jounce Therapeutics, Inc, a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company offers vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors, which is in Phase I/II clinical trial for the treatment of head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, gastric cancer, and other tumor types identified through its translational science platform.
Recommended Story: Equity Income
Get a free copy of the Zacks research report on Jounce Therapeutics (JNCE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
7 Stocks It May Be Time To Take Profits On
Should you or shouldn’t you? Many investors are wondering if it’s time to take some profit. With so much uncertainty in the market, there can be a temptation to take your profits and run. That may or may not be a good strategy. It’s true there are some speculative stocks that are going up on nothing but faith, trust, and pixie dust. But there are other stocks that may still be good buys despite continuing to grow.
Since the sell-off caused by the novel coronavirus and subsequent locking down of large portions of the economy, the stock market has recovered nearly all of its losses. The Federal Reserve has done its part by pledging to keep interest rates low for as long as it takes. New housing starts are up. Unemployment is coming down. There seems to be a lot of fuel for market bulls.
Still, if you’ve been holding one of the stocks in this presentation, it may be time for you to take some of the profits you’ve made. Many of the stocks in this presentation are being downgraded by analysts. And that means that there is likely to be downward pressure on the stock price.
View the "7 Stocks It May Be Time To Take Profits On".